Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 8/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606046 | 0.94 | FOLH1 (0.60) | FOLH1PTPN1BACE1BACE2NAALAD2 | |
| SCHEMBL30128626 | 0.94 | FOLH1 (0.60) | FOLH1PTPN1BACE1BACE2NAALAD2 | |
| SCHEMBL30436991 | 0.94 | FOLH1 (0.60) | FOLH1PTPN1BACE1BACE2NAALAD2 | |
| SCHEMBL1674773 | 0.94 | FOLH1 (0.63) | FOLH1PTPN1BACE1BACE2NAALAD2 | |
| SCHEMBL31410843 | 0.93 | FOLH1 (0.58) | FOLH1PTPN1BACE1BACE2NAALAD2 | |
| SCHEMBL31454946 | 0.93 | FOLH1 (0.61) | FOLH1BACE1BACE2NAALAD2CTSD | |
| SCHEMBL30553676 | 0.93 | FOLH1 (0.61) | FOLH1BACE1BACE2NAALAD2CTSD | |
| SCHEMBL29846196 | 0.93 | FOLH1 (0.61) | FOLH1BACE1BACE2NAALAD2CTSD | |
| SCHEMBL29883705 | 0.92 | FOLH1 (0.52) | FOLH1PTPN1BACE1BACE2CTSD | |
| SCHEMBL29400510 | 0.92 | FOLH1 (0.63) | FOLH1BACE1BACE2NAALAD2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027181-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-4388105-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | Beam Therapeutics Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240117059-A1 | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4324850-A2 | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FCRN-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023023515-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | BEAM THERAPEUTICS INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220361545-A1 | ENHANCED SALT COMPOSITIONS AND METHODS OF PREPARATION THEREOF | DOUXMATOK LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885PTPN1 3282/4885BACE1 4303/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885PTPN1 3282/4885BACE1 4303/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885PTPN1 3282/4885BACE1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.